复方丹参滴丸干预冠心病血瘀证凋亡相关基因临床分析

杨戈; 姜燕; 李军; 邢雁伟; 李小强

doi:10.13422/j.cnki.syfjx.2016200153

您当前的位置：

首页 >

文章列表页 >

复方丹参滴丸干预冠心病血瘀证凋亡相关基因临床分析

临床 | 更新时间：2024-01-04

- 复方丹参滴丸干预冠心病血瘀证凋亡相关基因临床分析
- Effect of Compound Danshen Dropping Pills in Interfering Apoptosis-related Genes of Coronary Heart Disease with Blood Stasis Syndrome
- 中国实验方剂学杂志 2016年22卷第20期页码：153-157
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金项目（30672765）;北京市自然科学基金项目（7062058）;博士后科学基金项目（20060390587）
- DOI：10.13422/j.cnki.syfjx.2016200153
  中图分类号： R285
- 纸质出版日期：2016
- 稿件说明：
移动端阅览
杨戈, 姜燕, 李军, 等. 复方丹参滴丸干预冠心病血瘀证凋亡相关基因临床分析[J]. 中国实验方剂学杂志, 2016,22(20):153-157.

YANG Ge, JIANG Yan, LI Jun, et al. Effect of Compound Danshen Dropping Pills in Interfering Apoptosis-related Genes of Coronary Heart Disease with Blood Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(20): 153-157.
杨戈, 姜燕, 李军, 等. 复方丹参滴丸干预冠心病血瘀证凋亡相关基因临床分析[J]. 中国实验方剂学杂志, 2016,22(20):153-157. DOI： 10.13422/j.cnki.syfjx.2016200153.

YANG Ge, JIANG Yan, LI Jun, et al. Effect of Compound Danshen Dropping Pills in Interfering Apoptosis-related Genes of Coronary Heart Disease with Blood Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(20): 153-157. DOI： 10.13422/j.cnki.syfjx.2016200153.

摘要

目的：研究复方丹参滴丸干预冠心病血瘀证凋亡相关基因，寻找复方丹参滴丸干预CHD血瘀证的有效靶点。方法：通过中西医结合病证临床研究，用逆转录-聚合酶链反应（RT-PCR）方法，观察常规治疗对照组治疗前后和复方丹参滴丸治疗组治疗前后凋亡相关基因的变化。结果：治疗组治疗后B淋巴细胞瘤-2（Bcl-2）Associated Transcription Factor1（BCLF1）mRNA表达显著降低（P<0.01），凋亡相关基因（Bcl-2 assaciated X protein，Bax）mRNA表达有降低趋势，两组治疗前后Bcl-2和凋亡信号转导分子（Cysteine asparate specific protease-3，Caspase-3）mRNA表达无明显差异。结论：复方丹参滴丸治疗后冠心病血瘀证患者相关基因凋亡相关转录因子BCLF1 mRNA表达显著减弱，凋亡相关基因Bax mRNA表达受到抑制，复方丹参滴丸可能通过调控细胞凋亡相关基因的表达，对冠心病血瘀证患者发挥治疗保护作用。

Abstract

Objective: In previous studies

we had screened and verified the relevant genes of coronary heart disease(CHD) with syndrome of blood stasis (SBS). Relevant genes of CHD with SBS were studied to reveal the pathobiology

and discover effective targets of DSP (compound Danshen dropping pills) in interfering CHD with SBS. Method: Reverse transcription-PCR was used to study the effect of DSP in interfering relevant genes and its clinic effect on CHD with SBS. Result: After treatment with DSP

the mRNA expression of BCLF1 (Bcl-2 associated transcription factor 1) decreased obviously(P<0.01)

and the mRNA expression of Bax (Bcl-2 assaciated X protein) showed a downward trend. But the mRNA expressions of Bcl-2 (B cell lymphoma/lewkmia-2) and Caspase-3 (cysteine asparate specific protease-3) had no difference before and after the treatment. Conclusion: The study proves that DSP can significantly reduce the mRNA expression of BCLF1 of relevant genes of CHD with SBS

and inhibit the mRNA expression of Bax. It treats CHD with SBS by regulating expressions of apoptosis-related genes of coronary heart disease with blood stasis syndrome.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

犀角地黄汤干预PKM2介导的一碳代谢途径调控脓毒症炎症反应的机制

线粒体质量控制调控肌少症发病机制及其中医药干预的研究进展

当归芍药散加味调控JNK/p38 MAPK通路改善痤疮炎症和凋亡的机制

子宫内膜异位症程序性细胞死亡和中医药干预作用研究进展

基于EGFR/PI3K/Akt信号通路探讨加味少腹逐瘀汤治疗子宫内膜异位症的作用机制